Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GSK3B | P49841 | 1/20 | 0.47 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.47 |
| ▸ | CNR2 | P34972 | 7/20 | 0.44 |
| ▸ | CNR1 | P21554 | 1/20 | 0.44 |
| ▸ | PKM | P14618 | 1/20 | 0.43 |
| ▸ | FAAH | O00519 | 3/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.43 |
| ▸ | MEN1 | O00255 | 1/20 | 0.43 |
| ▸ | TSHR | P16473 | 1/20 | 0.43 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.42 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.42 |
| ▸ | ITK | Q08881 | 1/20 | 0.41 |
| ▸ | POLB | P06746 | 3/20 | 0.41 |
| ▸ | ATM | Q13315 | 1/20 | 0.40 |
| ▸ | MAPT | P10636 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12269788 | 0.83 | GSK3B (0.45) | GSK3BDYRK1ACNR2CNR1PKM | |
| SCHEMBL12317927 | 0.78 | MAP2K4 (0.48) | ITK | |
| SCHEMBL12317929 | 0.78 | MAP2K4 (0.53) | DYRK1APKMKMT2AMEN1KDM4E | |
| SCHEMBL12317932 | 0.74 | ITK (0.53) | PKMKMT2AMEN1KDM4EHSD17B10 | |
| SCHEMBL12317933 | 0.72 | ATM (0.52) | PKMKMT2AMEN1TSHRKDM4E | |
| SCHEMBL12318101 | 0.72 | ITK (0.51) | KDM4EHSD17B10ITKPOLBMAPT | |
| SCHEMBL12318045 | 0.72 | MAPK1 (0.45) | GSK3BDYRK1AITK | |
| SCHEMBL12318479 | 0.71 | ITK (0.61) | GSK3BITK | |
| SCHEMBL12317853 | 0.70 | ROCK2 (0.43) | GSK3BDYRK1AITK | |
| SCHEMBL12318043 | 0.69 | AXL (0.58) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110212961-A1 | Pyrazole Derivatives as Kinase Inhibitors | BURNHAM INSTITUTE FOR MEDICAL RESEARCH | 2011-09-01 | — | — | US | disclosed |
| US-7951832-B2 | Pyrazole derivatives as kinase inhibitors | BURNHAM INSTITUTE FOR MEDICAL RESEARCH (US) | 2011-05-31 | — | — | US | disclosed |
| US-20090124621-A1 | PYRAZOLE DERIVATIVES AS KINASE INHIBITORS | BURNHAM INSTITUTE FOR MEDICAL RESEARCH (US) | 2009-05-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090124621-A1 | PYRAZOLE DERIVATIVES AS KINASE INHIBITORS | BRAF, MAP3K1, MAP3K3 | GSK3B 268/4885DYRK1A 756/4885CNR2 2599/4885 |
| US-20110212961-A1 | Pyrazole Derivatives as Kinase Inhibitors | BRAF, MAP3K1, MAP3K3 | GSK3B 268/4885DYRK1A 756/4885CNR2 2599/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.